Related Experiment Video
Updated: Oct 1, 2025

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
Retrospective Evaluation of Oral Glucose Tolerance Test in Young Patients with Transfusion-Dependent Beta-Thalassemia
Maria Dritsa1, Marina Economou1, Vasilios Perifanis2
11st Paediatric Department, School of Medicine, Hippokratio General Hospital, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Insights
Yearly oral glucose tolerance tests (OGTT) for thalassemia major (TM) patients in their second decade may not be necessary. New criteria could reduce testing by 46%, ensuring timely detection of glucose intolerance without unnecessary tests.
Area of Science:
- Endocrinology
- Hematology
- Pediatrics
Background:
- Current guidelines recommend annual oral glucose tolerance tests (OGTT) for thalassemia major (TM) patients starting at age 10.
- Glucose metabolism evaluation is crucial for managing TM complications.
Purpose of the Study:
- To retrospectively evaluate OGTTs in pediatric TM patients over a decade.
- To assess the necessity of yearly OGTTs during the second decade of life for TM patients.
Main Methods:
- Analysis of 170 OGTT tests from 39 TM patients (ages 10-19).
- Identification of patients with impaired glucose tolerance (IGT) or diabetes mellitus.
- Development of selective criteria for OGTT performance.
Main Results:
- Only 10% of tests showed impaired glucose tolerance (IGT), and 1.18% indicated diabetes mellitus.
- No significant differences in demographics, ferritin levels, or transfusion volume were found between patients with normal and abnormal glucose metabolism.
- Proposed criteria could reduce the number of OGTTs by 46.47% (from 170 to 91).
Conclusions:
- A small percentage of young, transfusion-dependent TM patients develop abnormal glucose metabolism in their second decade.
- Implementing specific selection criteria can significantly decrease the number of performed OGTTs.
- This approach allows for timely detection and intervention while reducing resource utilization.
Background:
Current guidelines recommend yearly evaluation of glucose metabolism with oral glucose tolerance test (OGTT) in patients with thalassemia major (TM) from their 10th year onwards.
Aims:
The aim of the study was to retrospectively evaluate all the OGTT tests performed in a single pediatric center during the last decade and assess the necessity of yearly performed OGTT in patients with TM during the second decade of life.
Results:
One hundred and seventy tests performed on 39 patients (24 boys) were included in the analysis. Mean age at the time of each OGTT was 14.15 ± 2.79 years. Seventeen tests (10%) in 8 patients (5 boys) were characterized as impaired glucose tolerance (IGT), whereas in 2 tests (1.18%), fasting glucose values were above 200 mg/dL (diabetes mellitus). Acknowledging the fact that there could be sporadic technical errors, especially in fasting glucose abnormal values, we selectively separated patients with either IGT and abnormal HOMA, MATSUDA, or QUICKI indices or persistently impaired fasting glucose or IGT. With these criteria, 7 patients (4 boys) were identified. No significant differences were observed in demographic and anthropometric parameters, ferritin levels, and mean volume of blood transfused in patients with a definite abnormal glucose metabolism. In order to address selection criteria for performing OGTT without missing a single patient with a definite glucose intolerance, these criteria should include (i) a first OGTT test at the initiation of puberty, (ii) OGTT in any patient with a fasting glucose above 100 mg/dL, and (iii) OGTT in any patient with a ΗΟΜΑ-IR index above 1.85 and yearly onwards. By adopting these criteria, total OGTT tests performed could have been reduced from 170 to only 91, translating to a significant reduction of 46.47%.
Conclusions:
Only a small percentage of young patients with transfusion-dependent b-thalassemia exhibit abnormal glucose metabolism during their second decade of life. By adopting specific selection criteria, one may avoid performing this time- and money-consuming test in a significant proportion of patients, albeit without sacrificing timely detection and intervention.
More Related Videos
06:59Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
Published on: November 13, 2016
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Diabetes Mellitus: Type 2 and Gestational
Hypoglycemia and Glucagon
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides